Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $480 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $480.
August 02, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Vertex Pharmaceuticals and maintained a price target of $480.
The reiteration of an Overweight rating and a high price target of $480 by Cantor Fitzgerald is a positive signal for investors, likely boosting short-term confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100